News

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential
FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...
Hosted on MSN23d
Scientists discover a rare missense variant in STAT6 that protects against asthma
The pathway to which STAT6 belongs is highly targeted by asthma biologics, with each drug targeting a single molecule within the T2 inflammatory response. Downregulating STAT6 in a clinical ...
Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy ...
Hosted on MSN22d
Gilead and LEO Pharma link on programmes for inflammatory conditions
“By partnering with LEO Pharma, we hope to explore the potential of the STAT6 pathway to bring forward an oral option for patients suffering from chronic inflammatory conditions.” Bank of ...
Nurix Therapeutics, Inc.: Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical app ...
scienceopen.com12d
Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer
Macrophage-colony stimulating factor (CSF-1) signaling through its receptor (CSF-1R) promotes the differentiation of myeloid progenitors into heterogeneous populations of monocytes, macrophages, ...
Frontiers20d
Transcriptomic signature can distinguish chronic neutrophilic leukemia from ambiguous neutrophilic leukemias
Pathways bearing a local false discovery rate (FDR ... and STATs (STAT1-4, STAT5A/B, and STAT6) was investigated. The results indicated that there was a positive correlation between CNL-5 risk scores ...
Frontiers29d
Editorial: State-of-the-art hypothesis-driven systems pharmacology and artificial intelligence approaches to decipher disease complexity
ProstaMine was applied to PCa subtypes with NKX3-1-loss and RB1-loss and successfully identified co-altered genes that function in canonical PCa signaling pathways such as MAPK ... specific ...
Yahoo Finance1d
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
“As the first STAT6-targeted agent in clinical development, we believe KT-621 has the opportunity to dramatically alleviate the burden of disease for those suffering from AD by offering an ...
eLife2d
DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma
This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...
manilatimes2d
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
"As the first STAT6-targeted agent in clinical development, we believe KT-621 has the opportunity to dramatically alleviate the burden of disease for those suffering from AD by offering an effective ...